Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Shares Outstanding (Weighted Average) (2019 - 2026)

ADC Therapeutics has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $154.1 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Weighted Average) at $154.1 million for Q1 2026, up 43.79% from a year ago — trailing twelve months through Mar 2026 was $154.1 million (up 43.79% YoY), and the annual figure for FY2025 was $127.1 million, up 30.78%.
  • Shares Outstanding (Weighted Average) reached $154.1 million in Q1 2026 per ADCT's latest filing, up from $127.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $154.1 million in Q1 2026 and bottomed at $220.0 in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $82.6 million (2024), compared with a mean of $73.7 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) crashed 67.16% in 2022 before it surged 7759054.95% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $81.1 million in 2022, then increased by 0.72% to $81.7 million in 2023, then grew by 18.91% to $97.2 million in 2024, then surged by 30.78% to $127.1 million in 2025, then rose by 21.31% to $154.1 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ADCT at $154.1 million in Q1 2026, $127.1 million in Q4 2025, and $136.4 million in Q3 2025.